MRVI vs BCAB

For growth investors, Maravai LifeSciences Holdings, Inc.

(MRVI) is the stronger pick with -80. 8% revenue growth year-over-year, versus -81. 8% for BioAtla, Inc. (BCAB). Analysts rate Maravai LifeSciences Holdings, Inc. (MRVI) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Maravai LifeSciences Holdings, Inc.

(MRVI) delivered a total return of -89. 4%, compared to -99. 8% for BioAtla, Inc. (BCAB). Over 10 years, the gap is even starker: MRVI returned -86. 8% versus BCAB's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioAtla, Inc.

(BCAB) is the lower-risk stock at 0. 51β versus Maravai LifeSciences Holdings, Inc. 's 2. 03β — meaning MRVI is approximately 298% more volatile than BCAB relative to the S&P 500.

By revenue growth (latest reported year), Maravai LifeSciences Holdings, Inc.

(MRVI) is pulling ahead at -80. 8% versus -81. 8% for BioAtla, Inc. (BCAB). On earnings-per-share growth, the picture is similar: Maravai LifeSciences Holdings, Inc. grew EPS 77. 1% year-over-year, compared to 29. 9% for BioAtla, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Maravai LifeSciences Holdings, Inc.

(MRVI) is the more profitable company, earning -262. 2% net margin versus -29. 8% for BioAtla, Inc. — meaning it keeps -262. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRVI leads at -431. 7% versus -29. 7% for BCAB. At the gross margin level — before operating expenses — BCAB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioAtla, Inc.

(BCAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51)). Maravai LifeSciences Holdings, Inc. (MRVI) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BCAB: -99. 7%, MRVI: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.